Entropy Neurodynamics Limited (ENP) - Total Liabilities

Latest as of December 2025: AU$1.13 Million AUD ≈ $797.70K USD

Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) has total liabilities worth AU$1.13 Million AUD (≈ $797.70K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Entropy Neurodynamics Limited annual equity growth to track the company's year-over-year net asset growth rate.

Entropy Neurodynamics Limited - Total Liabilities Trend (2018–2025)

This chart illustrates how Entropy Neurodynamics Limited's total liabilities have evolved over time, based on quarterly financial data. See Entropy Neurodynamics Limited free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Entropy Neurodynamics Limited Competitors by Total Liabilities

The table below lists competitors of Entropy Neurodynamics Limited ranked by their total liabilities.

Company Country Total Liabilities
Sinher Technology Inc
TW:4999
Taiwan NT$609.18 Million
Samebest Co Ltd
TWO:8489
Taiwan NT$1.08 Billion
Madusari Murni Indah Tbk PT
JK:MOLI
Indonesia Rp172.03 Billion
Mangalam Organics Limited
NSE:MANORG
India Rs4.21 Billion
dhSteel
KQ:021040
Korea ₩134.18 Billion
Seplat Petroleum Development Company PLC
LSE:SEPL
UK GBX3.22 Billion
K Seng Seng Corporation Bhd
KLSE:5192
Malaysia RM133.85 Million
Sumi Indo Kabel Tbk
JK:IKBI
Indonesia Rp25.31 Million

Liability Composition Analysis (2018–2025)

This chart breaks down Entropy Neurodynamics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Entropy Neurodynamics Limited (ENP) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 7.78 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 5.70 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.14 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Entropy Neurodynamics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Entropy Neurodynamics Limited (2018–2025)

The table below shows the annual total liabilities of Entropy Neurodynamics Limited from 2018 to 2025.

Year Total Liabilities Change
2025-06-30 AU$699.17K
≈ $494.71K
-61.85%
2024-06-30 AU$1.83 Million
≈ $1.30 Million
+4.47%
2023-06-30 AU$1.75 Million
≈ $1.24 Million
-63.50%
2022-06-30 AU$4.81 Million
≈ $3.40 Million
+85.57%
2021-06-30 AU$2.59 Million
≈ $1.83 Million
+69.81%
2020-06-30 AU$1.53 Million
≈ $1.08 Million
+442.75%
2019-06-30 AU$281.00K
≈ $198.83K
-10.94%
2018-06-30 AU$315.53K
≈ $223.26K
--

About Entropy Neurodynamics Limited

AU:ENP Australia Biotechnology
Market Cap
$42.72 Million
AU$60.38 Million AUD
Market Cap Rank
#22510 Global
#814 in Australia
Share Price
AU$0.04
Change (1 day)
+2.78%
52-Week Range
AU$0.03 - AU$0.04
All Time High
AU$0.04
About

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more